• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

Anti-parasite drug targets cancer-causing protein

New York - Researchers have found mebendazole, a widely prescribed drug used to treat parasitic infections, to be a a viable investigational agent for the treatment of chemotherapy-resistant malignant melanoma, ScienceDaily reports.

b>New York - Researchers have found mebendazole, a widely prescribed drug used to treat parasitic infections, to be a a viable investigational agent for the treatment of chemotherapy-resistant malignant melanoma, ScienceDaily reports.

The report, published in the journal Molecular Cancer Research and a phase 1 clinical trial is expected to begin next year. Researchers screened a library of 2,000 well-known drugs and identified benzimidazole agents for their ability to inhibit melanoma growth and induce cell death o malignant melanoma without harming normal melanocytes. The team chose mebendazole for further study because it is well-tolerated, orally available and contains anti-cancer properties, according to ScienceDaily.

Related Videos
E. James Song is featured in this video series.
E. James Song is featured in this video series.
Benjamin Lockshin, MD, FAAD, is featured in this series.
Benjamin Lockshin, MD, FAAD, is featured in this series.
Benjamin Lockshin, MD, FAAD, is featured in this series.
1 KOL is featured in this series.
2 KOLs are featured in this series.
1 KOL is featured in this series.
2 KOLs are featured in this series.
E. James Song is featured in this video series.
© 2024 MJH Life Sciences

All rights reserved.